Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Apr 14

PMID 29651407

Citations 309

Authors

Amila Suraweera

Kenneth J OByrne

Derek J Richard

Affiliations

Soon will be listed here.

Abstract

Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression. Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones. HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer. Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents. While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors. The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies. In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies. We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.

Citing Articles

Epigenetic drugs in cancer therapy.

Suraweera A, OByrne K, Richard D Cancer Metastasis Rev. 2025; 44(1):37.

PMID: 40011240 PMC: 11865116. DOI: 10.1007/s10555-025-10253-7.

Integrating alternative therapies in overcoming chemotherapy resistance in tumors.

Alqarni S, Khan N Mol Biol Rep. 2025; 52(1):239.

PMID: 39961936 DOI: 10.1007/s11033-025-10361-1.

HDAC10 and its implications in Sézary syndrome pathogenesis.

Pieniawska M, Rassek K, Skwara B, Zurawek M, Ziolkowska-Suchanek I, Visser L Front Cell Dev Biol. 2025; 13:1480192.

PMID: 39958888 PMC: 11825767. DOI: 10.3389/fcell.2025.1480192.

IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response.

Yao M, Yan W, Wang Y, Zhao Y, Xu X, Chen Y Exp Hematol Oncol. 2025; 14(1):15.

PMID: 39955584 PMC: 11829435. DOI: 10.1186/s40164-025-00605-y.

Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties.

Stopper D, Biermann L, Watson P, Li J, Konig B, Gaynes M J Med Chem. 2025; 68(4):4426-4452.

PMID: 39946728 PMC: 11867874. DOI: 10.1021/acs.jmedchem.4c02373.

References

Thurn K, Thomas S, Moore A, Munster P . Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011; 7(2):263-83. PMC: 3127396. DOI: 10.2217/fon.11.2. View

Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y . Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015; 34(49):5960-70. PMC: 4672172. DOI: 10.1038/onc.2015.46. View

Saleh-Gohari N, Helleday T . Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 2004; 32(12):3683-8. PMC: 484186. DOI: 10.1093/nar/gkh703. View

Robey R, Chakraborty A, Basseville A, Luchenko V, Bahr J, Zhan Z . Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm. 2011; 8(6):2021-31. PMC: 3230675. DOI: 10.1021/mp200329f. View

Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G . Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res. 2005; 29(7):739-48. DOI: 10.1016/j.leukres.2004.11.022. View

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

Marrocco-Tallarigo D, Centenera M, Scher H, Tilley W, Butler L . Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Rev Clin Pharmacol. 2011; 2(6):619-30. DOI: 10.1586/ecp.09.44. View

Arora A, Scholar E . Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315(3):971-9. DOI: 10.1124/jpet.105.084145. View

Venturelli S, Armeanu S, Pathil A, Hsieh C, Weiss T, Vonthein R . Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer. 2007; 109(10):2132-41. DOI: 10.1002/cncr.22652. View

10.

Pfeiffer M, Mulders P, Schalken J . An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate. 2010; 70(14):1524-32. DOI: 10.1002/pros.21187. View

11.

Munster P, Thurn K, Thomas S, Raha P, Lacevic M, Miller A . A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104(12):1828-35. PMC: 3111195. DOI: 10.1038/bjc.2011.156. View

12.

Luu T, Morgan R, Leong L, Lim D, McNamara M, Portnow J . A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008; 14(21):7138-42. PMC: 3543872. DOI: 10.1158/1078-0432.CCR-08-0122. View

13.

Campbell R, Sanchez E, Steinberg J, Shalitin D, Li Z, Chen H . Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol. 2009; 84(3):201-11. DOI: 10.1111/j.1600-0609.2009.01384.x. View

14.

Ismael G, Dornelles Rosa D, Mano M, Awada A . Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev. 2007; 34(1):81-91. DOI: 10.1016/j.ctrv.2007.08.001. View

15.

Sistigu A, Manic G, Obrist F, Vitale I . Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol. 2016; 3(2):e1053594. PMC: 4905370. DOI: 10.1080/23723556.2015.1053594. View

16.

Diyabalanage H, Granda M, Hooker J . Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 2012; 329(1):1-8. PMC: 3546543. DOI: 10.1016/j.canlet.2012.09.018. View

17.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S . Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(17):5187-5201. PMC: 5723438. DOI: 10.1158/1078-0432.CCR-17-0741. View

18.

Powis G, Mustacich D, Coon A . The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med. 2000; 29(3-4):312-22. DOI: 10.1016/s0891-5849(00)00313-0. View

19.

Basu A, Krishnamurthy S . Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010; 2010. PMC: 2929606. DOI: 10.4061/2010/201367. View

20.

Shabason J, Tofilon P, Camphausen K . Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med. 2011; 15(12):2735-44. PMC: 3112261. DOI: 10.1111/j.1582-4934.2011.01296.x. View